Noradrenergic input from sympathetic nerves to fibroblasts regulates lung fibrosis
Pulmonary fibrosis is a progressive, irreversible condition in which expansion of effector fibroblasts and extracellular matrix obliterates alveolar gas exchange regions of the lung through incompletely understood mechanisms. We found sympathetic nerve fibers in fibrotic alveolar regions enriched for alpha–smooth muscle actin–positive (α-SMA + ) effector fibroblasts and noradrenaline by applying optical clearing and whole-lung imaging to the bleomycin mouse model of lung fibrosis and multichannel immunofluorescence to explanted lung tissues from patients with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis–associated interstitial lung disease (SSc-ILD). Human lung fibroblasts cultured with sympathetic nerves displayed enhanced production of fibrotic markers, and sympathetic nerve–specific deletion of the nerve growth factor receptor neurotrophic receptor tyrosine kinase 1 mitigated bleomycin-induced lung fibrosis in mice. Pharmacologic inhibition of noradrenaline receptors, including α1-adrenoreceptors, mitigated collagen accumulation and pathologic remodeling in bleomycin-challenged mice and in human precision-cut lung slices. Accumulation of α-SMA + effector fibroblasts expressing α1-adrenoreceptor subtype D (ADRA1D) was observed in fibrotic mouse lungs and in explanted lung tissues from patients with IPF or SSc-ILD. Therapeutic deletion of Adra1d in α-SMA + effector fibroblasts suppressed fibrosis in the bleomycin model. Secondary analysis of single-cell RNA sequencing datasets from IPF or SSc-ILD lung explants revealed α1-adrenoreceptor antagonist–responsive, disease-specific programs in effector fibroblasts. Together, these studies show that a fibrogenic unit comprising sympathetic nerve–derived noradrenaline and ADRA1D + effector fibroblasts promotes lung fibrosis in disease-relevant modeling systems. Strategies targeting sympathetic innervation or α1-adrenoreceptors may provide previously unrecognized therapeutic opportunities in IPF, SSc-ILD, and related fibrotic conditions.
Authors
- Changwan Ryu (ORCID: https://orcid.org/0000-0001-6211-4327)
- Daisuke Okuno (ORCID: https://orcid.org/0009-0007-7616-7770)
- Tomokazu S. Sumida (ORCID: https://orcid.org/0000-0002-9806-2642)
- Maor Sauler (ORCID: https://orcid.org/0000-0001-5240-7978)
- Erica L. Herzog (ORCID: https://orcid.org/0000-0002-7508-8575)
- Angela Liu (ORCID: https://orcid.org/0000-0001-7902-538X)
- Huanxing Sun (ORCID: https://orcid.org/0000-0003-2397-4652)
- Buqu Hu (ORCID: https://orcid.org/0000-0001-7233-987X)
- Xueyan Peng (ORCID: https://orcid.org/0009-0006-6320-2592)
- Karam Al Jumaily (ORCID: https://orcid.org/0009-0005-0618-5151)
- Alexander Ghincea (ORCID: https://orcid.org/0000-0001-7404-9921)
- Genta Ishikawa (ORCID: https://orcid.org/0000-0002-8882-8288)
- Robert Homer (ORCID: https://orcid.org/0000-0002-2055-5885)
- Carol A. Feghali‐Bostwick (ORCID: https://orcid.org/0000-0002-6750-6407)
- John McGovern (ORCID: https://orcid.org/0009-0007-1310-3999)
- Sheeline Yu (ORCID: https://orcid.org/0009-0008-7650-7752)
- Tina Saber
- Ying Sun (ORCID: https://orcid.org/0009-0008-5636-4350)
Institutions
- Brigham and Women's Hospital (US)
- Albert Einstein College of Medicine (US)
- Harvard University (US)
- Medical University of South Carolina (US)
- University of Pittsburgh (US)
- University of South Florida (US)
- University of Michigan (US)
- Hospital of the University of Pennsylvania (US)
- Yale University (US)
- Michigan Medicine (US)
- Nagasaki University Hospital (JP)
- Columbia University (US)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/scitranslmed.adw3631
- Citations
- 3
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 9.29
Funders
- U.S. Department of Defense
- Pulmonary Fibrosis Foundation
- Yale University
- Francis Family Foundation
- National Scleroderma Foundation
- Greenfield Foundation
- National Institutes of Health
- Japan Society for the Promotion of Science
- National Heart, Lung, and Blood Institute
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Yale Center for Clinical Investigation, Yale School of Medicine